2020年8月22日

全球神经生物标志物市场将见证一个健康的10.02%的复合年增长率的预测期2019 - 2026。报告包含数据的基准年2018年和2017年的历史。神经障碍病例上升和增加技术进步的因素是市场的增长。的一些主要竞争对手目前在全球神经生物标志物市场无数的遏制;阿伯特;热费希尔科学公司;雅典娜诊断公司;Quanterix; Immunarray分公司。试剂盒;Bio-Rad实验室,Inc .,榕树生物标志物,公司,默克公司,F。罗氏公司有限公司,詹森全球服务有限责任公司,查尔斯河;先进的大脑监测,Inc ., Neurosteer; Quanterix;等等。得到这份报告@ https://www.databridgemarketresearch.com/request-a-sample/?的专属样本dbmr = global-neurological-biomarkers-market这个神经生物标志物的市场研究报告准备采用综合进步和最近的创新得到最美妙的结果。 The data and examination shrouded in the Neurological Biomarkers showcase report brings into light the sorts of customers, their inclinations about the item, their purchasing expectations and their thoughts regarding the upgrade of an item. A good number of top competitors are contemplated in this report to get the experiences on key industry examination of the key components affecting the market. Breakdown and estimations of significant industry patterns, showcase drivers, advertise restrictions, advertise size, piece of the pie and sales volume have been clarified very well in the report. Key Developments in the Market: In June 2019, Quanterix Corporation announced the acquisition of UmanDiagnostics AB which will help the company to strengthen their assay development and supply abilities. The antibody and Elisa kits supplied by UmanDiagnostics can help the company to detect Nf-L which can be used to treat, predict and track a variety of conditions, including ALS, multiple sclerosis and other. This acquisition will help the company to develop new digital biomarkers to improve the field of neurological condition diagnostics science In November 2017, Quanterix Corporation announced the launch of their new SR-X Ultra-Sensitive Biomarker Detection System. SR-X platform has the ability to detect neurological biomarkers that were historically observable only in cerebrospinal fluid. The SR-X has the ability to improve treatment of brain injuries and diseases by identifying neurological biomarkers much sooner and allowing us to consider the long-term effects and pathology of diseases Market Drivers Increasing demand for non-invasive diagnostic techniques for Alzheimer’s and Parkinson’s will drive the market growth Growing demand for personalized medicine for neurological disorders also accelerates the market growth Rising focus to create cost- effective biomarker testing will also propel the growth Growing demand for genomics biomarker will also propel the market growth Market Restraints Strict government regulation will hamper the market growth Emerging legal issues with early diagnosis of Alzheimer’s and Parkinson’s diseases also acts as a restricting factor for the growth of this market The absence of pre-analytical tests will also hinder the market growth To know more about the study @ https://www.databridgemarketresearch.com/reports/global-neurological-biomarkers-market Segmentation: Global Neurological Biomarkers Market By Product Type Functional Magnetic Resonance Imaging